Billionaire investor Stanley Druckenmiller's fund sold its entire position in Eli Lilly during the third quarter, as revealed in the latest filings. The move is notable as it follows his fund's previous exits from other high-flying growth stocks like Nvidia and Palantir Technologies over the past year. Eli Lilly's shares have climbed significantly, driven by the immense success of its weight-loss and diabetes drug portfolio. While the specific rationale for Druckenmiller's sale of LLY was not stated, the report suggests that the stock's advanced valuation likely played a role, a reason the investor has previously given for selling other appreciated stocks. Following the sale, Druckenmiller's fund opened new positions in Alphabet and Meta Platforms, which are described as the two cheapest stocks within the 'Magnificent Seven' group, suggesting a potential rotation into perceived value.